Previous 10 | Next 10 |
2024-02-01 15:27:39 ET Summary Today, we circle back on Simulations Plus, Inc., a health information services company focused on drug discovery and development software. Analysts have reissued Buy ratings on the stock, but the high valuation and potential competition from generati...
New version delivers on FDA collaborations and user feedback for expansion of non-oral delivery route models Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industrie...
2024-01-25 08:00:18 ET Simulations Plus Inc. (SLP) declaring a stock dividend of $0.06 per share on Ex-Date : January 26, 2024. Shareholders on record as of January 29, 2024 are eligible for the dividend. The payment date is scheduled for February 05, 2024, and the declaration was o...
2024-01-11 13:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Partnership aims to integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product development Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnol...
2024-01-03 19:54:09 ET Simulations Plus, Inc. (SLP) Q1 2024 Earnings Conference Call January 03, 2024, 05:00 PM ET Company Participants Tamara Gonzalez - Investor Relations, Financial Profiles Shawn O'Connor - Chief Executive Officer Will Frederick - Chief Financ...
2024-01-03 16:10:49 ET More on Simulations Plus Big Pharma's AI Ambitions: The Countdown For Simulations Plus Begins Simulations Plus, Inc. (SLP) Q4 2023 Earnings Call Transcript Simulations Plus director sells stock worth $2.3M - filing Seeking Alpha’...
Total revenue of $14.5 million and diluted earnings per share (EPS) of $0.10 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of mod...
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the following leadership changes effective January 3, 2024. “We are excited to announce...
2023-12-29 15:00:18 ET More on the markets Sentiment Speaks: The Fed Is Going To Put A Big Hurt On Everyone In 2024 5 Big Market Predictions For 2024 2024 Analyst Outlook: Lawrence Fuller On An Economic Soft Landing Scenario A Peak In Excess Liquidity May Mea...
News, Short Squeeze, Breakout and More Instantly...
Objective to define best practices for the use of novel PBK modeling strategies to support animal-free safety assessment of new chemicals Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance an...
Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulati...
2024-06-24 16:10:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...